CORRELATION BETWEEN MOLECULAR AND CLINICOHISTOLOGICAL CHAR- ACTERISTICS OF BREAST CANCER IN YOUNG WOMEN


  • L. Bacalîm Department of oncology, SMPhH “Nicolae Testemitsanu”
  • L. Sofroni Oncological Institute, Chisinau, Republic of Moldova
  • N. Corobcean Department of oncology, SMPhH “Nicolae Testemitsanu”
  • I. Chimencedji Oncological Institute, Chisinau, Republic of Moldova
  • Ox. Odobescu Department of oncology, SMPhH “Nicolae Testemitsanu”
  • N. Ghidirim Department of oncology, SMPhH “Nicolae Testemitsanu”

Abstract

CORRELATION BETWEEN MOLECULAR AND CLINICOHISTOLOGICAL CHAR- ACTERISTICS OF BREAST CANCER IN YOUNG WOMEN

References

1. Morandi, I. Plaza-Menacho, and C. M. Isacke, “RET in breast cancer: functional and therapeu- tic implications, ”Trends in Molecular Medicine, vol. 17, no. 3, pp. 149–157, 2011.



2. Bae SY, Kim S, Lee JH, et al. Poor prognosis of single hormone receptor-positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 2015;15:138.



3. Bal O, Yalcintas Arslan U, Durnali A, et al. Progesterone receptor status in determining the prognosis of estrogen receptor positive/HER2 negative breast carcinoma patients. J BUON. 2015;20(1):28–34.



4. Cancello G, Maisonneuve P, Rotmensz N, et al. Progesterone receptor loss identifies luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol. 2013;24(3):661–668



5. Coates AS, Winer EP, Goldhirsch A, et al. Tailoring therapies improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol. 2015;26(8):1533–1546.



6. Couch FJ, Hart SN, Sharma P, et al. Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. J Clin Oncol. 2015;33:304–311.



7. Fattaneh A. Tavassoli, MD. Correlation Between Gene Expression Profiling-Based Molecular and Morphologic Classification of Breast Cancer. Internaţional Journal of Surgical Pathology Supplement to 18(3). 2010; 18: 167S-169S.



8. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon: International Agency for Research on Cancer; 2014.



9. Ellis IO, Cornelisse CJ, Schnitt SJ, Sasco AJ, Sastre-Garau X, Kaaks R. Invasive breast carcino- mas. In: Tavassoli FA, Devilee P, editors. WHO Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs. Lyon: IARC Press; 2003. pp. 13–19.



10. Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Thera- py of Early Breast Cancer 2013. Ann Oncol. 2013;24(9):2206–2223.



11. Harris JR, Lippman ME, Morrow M and Kent Osborne C (2010) Diseases of the Breast, 4th edn. Philadelphia: Lippincott Williams & Wilkins.



12. J. Cheng, C. Zhang, and D. J. Shapiro, “A functional serine 118 phosphorylation site in estrogen receptor-α is required for down-regulation of gene expression by 17β-estradiol and 4-hydroxy- tamoxifen,” Endocrinology, vol. 148, no. 10, pp. 4634–4641, 2007.



13. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.1.J. D. Marotti, L. C. Collins, R. Hu, and R. M. Tamimi, “Estrogen receptor-
Published
2017-12-27
How to Cite
Bacalîm, L., Sofroni, L., Corobcean, N., Chimencedji, I., Odobescu, O., & Ghidirim, N. (2017). CORRELATION BETWEEN MOLECULAR AND CLINICOHISTOLOGICAL CHAR- ACTERISTICS OF BREAST CANCER IN YOUNG WOMEN. Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 1(3), 36-40. https://doi.org/10.29256/01.03.2017.escbm12
Section
Selected abstracts